LTPA2016043I1 - 4[[4-[[4-(2-Cyanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska - Google Patents

4[[4-[[4-(2-Cyanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska

Info

Publication number
LTPA2016043I1
LTPA2016043I1 LTPA2016043C LTPA2016043C LTPA2016043I1 LT PA2016043 I1 LTPA2016043 I1 LT PA2016043I1 LT PA2016043 C LTPA2016043 C LT PA2016043C LT PA2016043 C LTPA2016043 C LT PA2016043C LT PA2016043 I1 LTPA2016043 I1 LT PA2016043I1
Authority
LT
Lithuania
Prior art keywords
amino
cyanoethenyl
dimethylphenyl
pyrimidinyl
benzonitrile
Prior art date
Application number
LTPA2016043C
Other languages
English (en)
Lithuanian (lt)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38091637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTPA2016043(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from MYPI20043578A external-priority patent/MY169670A/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of LTPA2016043I1 publication Critical patent/LTPA2016043I1/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Hybrid Cells (AREA)
LTPA2016043C 2004-09-02 2016-12-20 4[[4-[[4-(2-Cyanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska LTPA2016043I1 (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
MYPI20043578A MY169670A (en) 2003-09-03 2004-09-02 Combinations of a pyrimidine containing nnrti with rt inhibitors
PCT/EP2004/052028 WO2005021001A1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
EP05101467 2005-02-25
EP05108086.9A EP1632232B3 (en) 2004-09-02 2005-09-02 Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile

Publications (1)

Publication Number Publication Date
LTPA2016043I1 true LTPA2016043I1 (lt) 2017-01-10

Family

ID=38091637

Family Applications (2)

Application Number Title Priority Date Filing Date
LTPA2016043C LTPA2016043I1 (lt) 2004-09-02 2016-12-20 4[[4-[[4-(2-Cyanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska
LTPA2016042C LTC1632232I2 (lt) 2004-09-02 2016-12-20 4[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTPA2016042C LTC1632232I2 (lt) 2004-09-02 2016-12-20 4[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska

Country Status (21)

Country Link
EP (1) EP1632232B3 (https=)
JP (1) JP4912309B2 (https=)
CN (1) CN104586850A (https=)
AT (1) ATE508748T1 (https=)
BR (1) BRPI0514871A (https=)
CY (3) CY1112249T1 (https=)
DK (1) DK1632232T6 (https=)
EA (1) EA013686B1 (https=)
ES (1) ES2371442T7 (https=)
FR (2) FR16C1023I2 (https=)
HK (1) HK1210029A1 (https=)
HU (2) HUS1600060I1 (https=)
IL (1) IL181650A (https=)
LT (2) LTPA2016043I1 (https=)
ME (1) ME01246B (https=)
MX (1) MX2007002595A (https=)
NI (1) NI200700068A (https=)
NO (3) NO340654B1 (https=)
PT (1) PT1632232E (https=)
RS (1) RS51923B2 (https=)
SI (1) SI1632232T1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
BRPI0707179A2 (pt) * 2006-01-20 2011-04-26 Tibotec Pharm Ltd tratamento de longo termo de infecção por hiv
CL2008000746A1 (es) 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
SG10201509521WA (en) * 2010-11-19 2015-12-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
JP5870183B2 (ja) * 2011-04-15 2016-02-24 エムキュア ファーマシューティカルズ リミテッド リルピビリン中間体の合成方法
EP2628732A1 (en) * 2012-02-20 2013-08-21 Sandoz AG Novel crystalline form of rilpivirine hydrochloride
EP2604593A1 (en) 2011-12-14 2013-06-19 Sandoz AG Polymorph of Rilpivirine hydrochloride and its use as antiviral
WO2013087794A1 (en) 2011-12-14 2013-06-20 Sandoz Ag Polymorph of rilpivirine hydrochloride and its use as antiviral
WO2013153161A2 (en) * 2012-04-11 2013-10-17 Sandoz Ag Novel polymorph of rilpivirine hydrochloride
WO2013153162A1 (en) * 2012-04-11 2013-10-17 Sandoz Ag Polymorph of rilpivirine hydrochloride
CN103570688B (zh) * 2012-07-19 2016-06-08 中国科学院上海药物研究所 2，5-二氨甲基吡嗪类化合物、其药物组合物、制备方法和用途
GR1008965B (el) * 2015-12-02 2017-02-28 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει δαρουναβιρη και μεθοδος παρασκευης αυτου
RU2616267C1 (ru) * 2016-01-25 2017-04-13 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма индинавира немедленного высвобождения и способ ее получения
WO2018077815A1 (en) * 2016-10-24 2018-05-03 Janssen Sciences Ireland Uc Dispersible compositions
JP7287906B2 (ja) * 2017-06-30 2023-06-06 ヴィーブ ヘルスケア カンパニー 組み合わせ並びにその使用及びそれによる治療
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307543B1 (en) * 1998-09-10 2001-10-23 Silicon Image, Inc. Bi-directional data transfer using two pair of differential lines as a single additional differential pair
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
KR101140785B1 (ko) * 2002-08-09 2012-05-03 얀센 파마슈티카 엔.브이. 4-〔〔4-〔〔4-（2-시아노에테닐）-2,6-디메틸페닐〕아미노〕-2-피리미디닐〕아미노〕벤조니트릴의 제조방법
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
BRPI0407329A (pt) * 2003-02-07 2006-01-10 Janssen Pharmaceutica Nv Derivados de pirimidina para a prevenção de infecção de hiv

Also Published As

Publication number Publication date
CY2016050I1 (el) 2017-07-12
CN104586850A (zh) 2015-05-06
SI1632232T1 (sl) 2011-09-30
MX2007002595A (es) 2007-04-25
ES2371442T3 (es) 2012-01-02
EP1632232B1 (en) 2011-05-11
RS51923B (sr) 2012-02-29
IL181650A (en) 2012-08-30
NO340654B1 (no) 2017-05-22
ME01246B (me) 2013-06-20
FR16C1025I1 (fr) 2017-02-03
JP4912309B2 (ja) 2012-04-11
CY1112249T1 (el) 2015-12-09
ATE508748T1 (de) 2011-05-15
IL181650A0 (en) 2007-07-04
PT1632232E (pt) 2011-08-02
ES2371442T7 (es) 2022-05-12
BRPI0514871A (pt) 2008-06-24
EA013686B1 (ru) 2010-06-30
FR16C1023I1 (fr) 2017-02-03
HUS1600060I1 (hu) 2017-01-30
NO2017065I1 (no) 2017-11-21
NO2017063I1 (no) 2017-11-21
EA200700536A1 (ru) 2007-08-31
EP1632232B3 (en) 2022-03-30
NI200700068A (es) 2016-09-29
LTC1632232I2 (lt) 2024-09-10
FR16C1023I2 (fr) 2025-11-21
RS51923B2 (sr) 2022-05-31
FR16C1025I2 (fr) 2025-11-21
DK1632232T3 (da) 2011-08-22
DK1632232T6 (da) 2022-04-19
HK1210029A1 (en) 2016-04-15
LTPA2016042I1 (lt) 2017-01-10
JP2008511592A (ja) 2008-04-17
HUS1600061I1 (hu) 2017-01-30
CY2016051I1 (el) 2017-07-12
NO20071745L (no) 2007-04-02
EP1632232A1 (en) 2006-03-08

Similar Documents

Publication Publication Date Title
LTPA2016043I1 (lt) 4[[4-[[4-(2-Cyanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska
NO2014030I1 (no) (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]-amino]-2-pyrimidinyl]-amino]-benzonitril("Rilpivirine") samt enhver terapeutisk form derav som er dekket av det aktuelle patentet så som farmasøytisk akseptable salter av Rilpivirie innbefattende hydrokloridsaltet av Rilpivirine, og emtricitabine.
MY123650A (en) Pharmaceutical compositions comprising a hmg coa reductase inhibitor
WO2005037824A3 (de) Verfahren zur herstellung von aminocrotonylverbindungen
PL373679A1 (en) Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
PL1632232T3 (pl) Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
WO2010030201A3 (en) Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid
CR9032A (es) Fumarato de 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino-2- pirimidinil)amino)benzonitrilo
UA92467C2 (ru) Гидрохлорид 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
DE60302951D1 (de) Pyroglutaminsäure-salz von Amlodipin
HRP20110563T1 (en) Salt of 4[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile